Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Cytomegalovirus infections market completely controlled by Roche's Valcyte

Industry Sector

Healthcare and Medical

Published

4 February 2013

Author

Alex De Angelis

Type of News

Market

The global cytomegalovirus (CMV) infections market has been forecast to increase at a compound annual growth rate (CAGR) of 6.29% over the next eight years, increasing from a valuation of $685.50 million in 2011 to hit a market value of $1.12 billion by 2019.

Human cytomegalovirus is a species of virus that belongs to the viral family known as Herpesviridae or herpesviruses. It is typically abbreviated as HCMV and is alternatively known as Human herpesvirus 5 (HHV-5).

Within Herpesviridae, HCMV belongs to the Betaherpesvirinae subfamily, which also includes cytomegaloviruses from other mammals.

Although they may be found throughout the body, HCMV infections are frequently associated with the salivary glands.

HCMV infection is typically unnoticed in healthy people, but can be life-threatening for the immunocompromised, such as HIV-infected persons, organ transplant recipients, or new born infants.

Roche has a strong presence in the CMV market with Valcyte, which is the only branded product for the treatment of CMV infections. The company is likely to maintain its competitive position until the generalisation of Valcyte in 2013 in the US and its patent expiry in 2015 in Europe.

The current market competition in the CMV market is weak, as Valcyte is the only branded drug for the treatment of CMV. Valcyte is a prodrug of ganciclovir with improved bioavailability, and is considered to be efficacious and safe for the treatment of CMV patients.

The CMV market will see the entrance of new companies that focus on three important strategies: first, companies focusing on novel mechanisms of action beyond DNA polymerase inhibitors; second, companies targeting transplant patients; and third, companies developing prophylactic products (40% of the pipeline products are being developed for CMV prophylaxis).

These strategies are expected to provide a distinct opportunity for pharmaceutical companies to build up their commercial presence in the CMV infections market.

For more information on the cytomegalovirus infections market, see the latest research: Cytomegalovirus Infections Market

Follow us on Twitter @CandMResearch

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings